Navigation Links
GSK'S Pazopanib Shows Positive Results in Patients with Advanced,Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC), ovarian cancer and soft tissue sarcoma (STS). These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.

Pazopanib is an oral, investigational angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit, important proteins in the angiogenic process. Angiogenesis, which is the growth of new blood vessels in the body, plays a critical role in the growth and spread of tumors. (1,2)

Renal cell carcinoma study (Abstract 5031) (3)

This ongoing Phase II randomized discontinuation study is evaluating patients with advanced or metastatic RCC who have not received prior systemic therapy or have failed one prior therapy (cytokine or bevacizumab-containing regimen). All patients received 800 mg of pazopanib taken orally, once-daily during a 12 week lead-in period. Based on data available on 60 patients at the time of a planned interim analysis, the Independent Data Monitoring Committee (IDMC) recommended that randomization to placebo for patients with stable disease should be discontinued. The study continued as an open-label, single- arm study with all patients receiving pazopanib.

The preliminary week 12 response rate for all 225 patients was 27%. In addition, stable disease was achieved in 46% of patients for a total disease control rate of 73%. Responses have been observed beyond week 12, and the overall response rate will be reported at study completion. Response was determined according to RECIST (Response Evaluation Criteria In Solid Tumors) which is a set of published rules that defines when
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Mass., May 12, 2011 PLC Systems Inc. (OTCBB: ... today announced it will demonstrate its innovative new product, ... Association of Percutaneous Cardiovascular Interventions (EAPCI).  More than 11,000 ... expected to attend this event, which will take place ...
... CVS Caremark was selected as one of 20 finalists ... Health Care Consumer Empowerment and Protection. URAC, the nation,s ... 12th Annual Quality Summit, October 4-6, 2011 in Chicago, ... Pharmacy Advisor program was selected by a distinguished panel ...
Cached Medicine Technology:PLC to Demonstrate RenalGuardĀ® at EuroPCR 2011 2PLC to Demonstrate RenalGuardĀ® at EuroPCR 2011 3CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 2CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 3
(Date:4/24/2014)... A Finnish team of researchers was the first in ... which is a tumour of the jaw. , Ameloblastoma ... recur after treatment. Ameloblastoma is most often found in ... by surgery, often resulting in tissue deficiencies in the ... suitable drug therapy could reduce the need for surgery ...
(Date:4/24/2014)... the University of York reveals that a process that ... nervous system may also play a pivotal role in ... led by Dr Will Brackenbury, a Medical Research Council ... studied how voltage-gated sodium channels assist in the metastasis ... membranes of excitable cells, such as neurons, where they ...
(Date:4/23/2014)... SPOKANE, Wash.Researchers at Washington State University Spokane have ... are about to nod off behind the wheel. ... steering wheel movementswhich are more variable in drowsy ... to currently available video-based driver drowsiness detection systems. ... detect when a car is drifting out of ...
(Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
(Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
... Highlights Key Issues and Offers Suggestions on ... Improvements for Hospital Administrators, NEW YORK, March ... delivery of a baby is a significant decision. But,there are ... departments,around the country that must function properly in order to ...
... on more than 17,000 people with coronary artery disease ... Treatment with an ACE inhibitor drug was as effective ... high-risk group of patients as a newer and more ... has found. , The study of more than 17,000 ...
... ANN ARBOR, Mich. An international blood pressure study ... significant that the study has been stopped early ... way high blood pressure is treated worldwide. , ... people who had high blood pressure and other cardiovascular ...
... 2008 New data from a clinical trial ... patients living with type 2 diabetes, ACTOS® (pioglitazone ... arteries compared to glimepiride, and prevented progression compared ... PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic ...
... new,public health campaign created by an alliance of ... in Washington, DC. The program,called EX(R), will change ... quitting, and guide them to valuable free resources ... Fairness Doctrine was applied to,tobacco in 1968-1970 have ...
... Industry Leaders,Association (RILA) today filed a friend-of-the-court (amicus) ... Court of Appeals for,the Ninth Circuit challenging the ... The case, Golden Gate Restaurant Association v. City ... Health Care Security Ordinance,which mandates health insurance coverage ...
Cached Medicine News:Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4Health News:ACE Inhibitor as Effective as More Expensive Blood Pressure Drug 2Health News:2-drug blood pressure therapy lowers cardiovascular risk 2Health News:2-drug blood pressure therapy lowers cardiovascular risk 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:New National Public Health Program Shows Smokers How to Become an EX 2Health News:New National Public Health Program Shows Smokers How to Become an EX 3Health News:New National Public Health Program Shows Smokers How to Become an EX 4Health News:New National Public Health Program Shows Smokers How to Become an EX 5Health News:Retail Industry Leaders Association Files Amicus in California Health Care Litigation 2
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... Building on over 20 years of ... platforms for the Life Sciences, the ... flexibility and possibilities for expansion according ... new easy-to-use software, Freedom EVOware, each ...
... (OSS) from Biomet Inc. offers the ... specifically for orthopaedic surgeons and oncologists ... their patients: significant bone loss, ligamentous ... arthroplasties, and multiple hip revision arthroplasties. ...
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
Medicine Products: